CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.

Akiko Shimazaki, Makoto Kubo, Kanako Kurata, Yuka Takao, Saori Hayashi, Yurina Harada, Hitomi Kawaji, Kazuhisa Kaneshiro, Mai Yamada, Masaya Kai, Masafumi Nakamura

Anticancer research 2022 Aug

filter terms:

Abnormalities in the cyclin D1-CDK4/6 complex have been implicated in breast cancer proliferation and resistance to treatment. Recently, new drugs have been developed to target CDK4/6. Meanwhile, liquid biopsy has received great interest in oncology. In this study, we analyzed cyclin D1 gene (CCND1) copy number variation (CNV) in circulating tumor DNA (ctDNA) from luminal B breast cancer patients. This study included 31 patients with luminal B breast cancer who underwent resection. We analyzed CCND1 CNV in ctDNA by digital droplet PCR. Of the 31 luminal B breast cancers, CCND1 CNV was positive in 5 cases. Patients with CCND1 CNV positivity had significantly shorter recurrence-free survival than patients with negative CCND1 CNV. CCND1 CNV in ctDNA was associated with poor prognosis in patients with luminal B breast cancer. This biomarker could be a useful prognostic factor. Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Citation

Akiko Shimazaki, Makoto Kubo, Kanako Kurata, Yuka Takao, Saori Hayashi, Yurina Harada, Hitomi Kawaji, Kazuhisa Kaneshiro, Mai Yamada, Masaya Kai, Masafumi Nakamura. CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients. Anticancer research. 2022 Aug;42(8):4071-4077